Introduction {#Sec1}
============

Glaucoma is a leading cause of visual disability and irreversible blindness that affects approximately 70 million people worldwide \[[@CR1], [@CR2]\]. Current glaucoma treatment options are focused on lowering intraocular pressure (IOP), with the ultimate goal of preserving optic nerve health and preventing visual field (VF) loss. Indeed, growing evidence has highlighted the association between an elevated IOP and the thinning of the retinal nerve fiber layer (RNFL) and the ganglion cell inner plexiform layer (GCIPL) \[[@CR3]\]. Available therapeutic options to decrease IOP include medication, laser treatment, micro-invasive glaucoma surgery (MIGS) implants or trabecular excision, glaucoma drainage devices, or traditional incisional filtering surgery.

Pharmacological treatment, however, is limited by poor adherence, local and systemic side effects, costs, and difficulties with instillation \[[@CR4]--[@CR6]\]. Laser trabeculoplasty is a relatively conservative intervention for mild IOP reduction, but it does induce inflammation and has a limited interval of IOP reduction \[[@CR7]\]. Traditional incisional filtering surgeries are usually regarded as the best way to quickly and substantially drop the IOP, but they are associated with significant complications such as hypotony, choroidal detachment, bleb infection or leak, and endophthalmitis \[[@CR8]--[@CR10]\]. Given these risks, several of which may cumulate over time, filtering procedures are often reserved for cases resistant to topical ocular hypotensive drugs and laser treatments.

If the risks of filtering surgery outweigh the potential benefits, ab interno micro-invasive glaucoma surgery (MIGS) may offer a propitious alternative. In the past decade, the glaucoma field has seen the increasing use of MIGS procedures, with the first US FDA-approved MIGS implant being the iStent trabecular micro-bypass (iStent^®^, Glaukos Corporation, San Clemente, CA, USA) \[[@CR11], [@CR12]\]. This stent allows circumvention of the damaged trabecular meshwork by creating a direct route from the anterior chamber to Schlemm's canal. Considerable evidence has shown the stents' ability to provide meaningful postoperative reductions in IOP and medication burden for up to 5 years with or without concomitant cataract surgery, and in various subtypes and severities of glaucoma \[[@CR11]--[@CR17]\]. Moreover, these benefits have occurred with favorable safety and minimal disruption to ocular structures.

More recently, the second-generation iStent Inject^®^ trabecular micro-bypass stent (Glaukos Corporation) has been developed to reduce IOP in a manner similar to the original iStent. Like the first-generation iStent, iStent Inject stents are made of biocompatible, medical-grade titanium. The iStent Inject device consists of an injector preloaded with two heparin-coated titanium stents, each having a central lumen and four side outlets to allow for multidirectional aqueous outflow. The stents are placed ab interno through two separate regions of the trabecular meshwork into Schlemm's canal, where aqueous humor subsequently flows into collector channels en route out of the eye. The two stents are able to tap into up to 6 clock hours (i.e., half of the total span of the angle) of collector channels. The placement of stents in two separate areas increases accessibility to more collector channels for aqueous humor outflow, potentially enabling a greater IOP reduction.

Previous studies have highlighted the efficacy of the iStent Inject with and without concomitant cataract surgery in reducing the IOP and medication burden \[[@CR18]--[@CR27]\]. In this study, we present a large consecutive case series of eyes undergoing iStent Inject implantation with concomitant cataract surgery by a single surgeon at an academic ophthalmology center in Montreal, Canada. With a postoperative follow-up of 12 months, this study provides real-world data on IOP and medication reduction while also reporting on safety outcomes such as CDVA, VF, and RNFL and GCIPL thicknesses in eyes with various types and severities of glaucoma.

Methods {#Sec2}
=======

Study Design and Eligibility Criteria {#Sec3}
-------------------------------------

This single-surgeon, longitudinal consecutive case series assessed 12 months' worth of outcomes following iStent Inject implantation with cataract surgery in eyes affected by various types and severities of glaucoma. Preoperative inclusion criteria allowed for any operated patients with cataract and coexisting glaucoma \[including primary open-angle (POAG), primary angle closure (PACG), normal-tension (NTG), pseudoexfoliative (PXFG), and pigmentary (PG) glaucoma\]; with glaucomatous damage on retinal nerve fiber layer imaging, ganglion cell analysis, or VF; with a corrected distance visual acuity (CDVA) of 20/200 or better; with trabecular meshwork visible in the nasal angle on gonioscopy; and with the need for IOP or medication reduction. Any glaucoma severity was allowed, with severity classified according to the Hodapp--Anderson--Parrish visual field criteria (mild: VF MD no worse than − 6 dB; moderate: VF MD worse than − 6 dB but no worse than − 12 dB; severe: VF MD worse than − 12 dB) \[[@CR28]\].

Eyes were ineligible for surgery if they had nasal peripheral anterior synechiae or disorders inhibiting visualization of the nasal angle; elevated episcleral venous pressure; and chronic or acute ocular inflammation. The study was approved by the Ethics Committee of the Hôpital Maisonneuve-Rosemont in Montreal, Canada. All procedures performed were in accordance with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Written informed consent was obtained from all individual participants included in the study. Although analysis of this dataset was originally retrospective, patients were followed prospectively toward the end of the follow-up period with the intent of compiling a prospective case series to study longitudinal outcomes. At the time of surgery and publication of this report, iStent Inject was approved for POAG patients with mild-to-moderate disease severity. For this reason, a subgroup analysis was completed specifically for the eyes that matched those criteria (*n* = 53).

Stent and Surgical Technique {#Sec4}
----------------------------

The iStent Inject trabecular micro-bypass system is preloaded with two biocompatible, heparin-coated, titanium stents. Each micro-scale stent is designed for retention in the trabecular meshwork and has multiple lateral outlet lumina to allow for aqueous humor outflow from the anterior chamber, thereby decreasing IOP. The symmetrically designed structure of the stent enables it to be implanted in either the right or left eye, and by either the right or left hand of the surgeon. At the start of each surgery, in order to ensure maximal proximity of the stent to the collector channel ostia, two separate areas located at least two clock hours apart in the nasal angle with greater trabecular pigmentation \[[@CR29]\] or with evidence of focal blood reflux \[[@CR30]\] were identified and marked at the corneal limbus using a sterile marker. A standard phacoemulsification incision was made, through which the injector was advanced ab interno to the nasal trabecular meshwork. The surgeon then activated a release button to implant the stents into the trabecular meshwork adjacent to the limbal markings. This was followed by standard phacoemulsification cataract surgery through the same clear corneal incision. After surgery, subjects received oral acetazolamide (500 mg on the first evening), topical moxifloxacin (3 times per day for 1 week), topical nepafenac (3 times per day for 1 month), and a 2-week regimen of topical loteprednol (tapered from 4 times per day). Subjects' preexisting glaucoma medication regimens were discontinued or modified based on disease severity and postoperative IOP.

Study Outcomes and Data Analysis {#Sec5}
--------------------------------

Efficacy measures observed over 12 months postoperatively included mean IOP and medication usage, as well as proportional analyses of eyes with IOP ≤ 18, ≤ 15, and ≤ 12 mmHg; eyes on 0 or ≥ 2 medications; and eyes with reductions of ≥ 0, ≥ 1, or ≥ 2 medication(s) versus their preoperative state. Safety measures included noting any intra- and postoperative adverse events, corrected-distance visual acuity (CDVA), cup-to-disc ratio (CDR), visual field mean deviation (VF MD), increase in glaucoma medications for uncontrolled IOP, and secondary glaucoma surgeries.

Efficacy and safety measures were evaluated over the course of 12 months using repeated-measure analysis of variance (ANOVA). For variables with a significant 12-month change, linear regression models were used to assess predictors of response. All statistical analyses were performed using SPSS Statistics 25.0 (IBM, Armonk, NY, USA), with significance set at *p* \< 0.05.

Results {#Sec6}
=======

Demographics {#Sec7}
------------

A total of 118 eyes from 71 patients with a 12-month follow-up dataset are presented in this consecutive case series. Diagnoses consisted of POAG (*n* = 64), PACG (*n* = 23), NTG (*n* = 16), PXFG (*n* = 10), and PG (*n* = 5). Disease severity did not differ across different glaucoma subtypes (*p* = 0.169). The majority of the eyes (81%) had mild or moderate glaucoma, while 19% had severe disease. Half of the eyes had no prior glaucoma surgery, 30% had prior incisional glaucoma surgery, and 20% had previous laser peripheral iridotomy, which consisted of all PACG eyes (*n* = 23) as well as a PXFG eye with narrow angles. The mean preoperative IOP was 17.00 ± 3.82 mmHg on a mean of 2.31 ± 1.33 medications. The demographics and baseline clinical characteristics of the patients are presented in Table [1](#Tab1){ref-type="table"}.Table 1Demographic and preoperative ocular characteristicsVariable*N* = 118 eyes of 71 subjectsAge at time of surgery (years)68.56 ± 8.74Gender (male: female)59:59Eye (OD: OS)56:62History of prior glaucoma interventions % (*n*) Laser peripheral iridotomy20.3% (24/118) Selective laser trabeculoplasty28.0% (33/118) Trabeculectomy1.7% (2/118)Type of glaucoma Primary open angle glaucoma54.2% (64/118) Primary angle closure glaucoma19.5% (23/118) Normal-tension glaucoma13.6% (16/118) Pseudoexfoliative glaucoma8.5% (10/118) Pigmentary glaucoma4.2% (5/118)Intraocular pressure (mmHg)17.00 ± 3.82Glaucoma medications2.31 ± 1.33Corrected distance visual acuity (LogMAR)0.17 ± 0.22Cup to disc ratio0.70 ± 0.12Visual field---mean deviation (dB)− 6.57 ± 6.09Visual field---pattern standard deviation (dB)4.59 ± 2.78Retinal nerve fiber layer thickness (μm)71.10 ± 12.62Ganglion cell inner plexiform layer thickness (μm)67.72 ± 9.12Mean ± standard deviations are presented where applicable

Efficacy {#Sec8}
--------

At the 12-month mark following cataract surgery combined with implantation of iStent Inject, both IOP and medication burden showed significant reductions that had been maintained throughout follow-up. Mean IOP reduced by 17.8%, from 17.00 ± 3.83 mmHg to 13.97 ± 2.65 with a large effect size (*p* \< 0.001,*η*^2^ = 0.411, 95% confidence interval (CI) − 3.70 to − 2.37) (Fig. [1](#Fig1){ref-type="fig"}, Table [2](#Tab2){ref-type="table"}). As illustrated in Fig. [2](#Fig2){ref-type="fig"}, approximately 93% of eyes achieved IOP ≤ 18 mmHg at the 12-month mark (versus 69% preoperatively), 70% of eyes achieved IOP ≤ 15 mmHg (versus 42% preoperatively), and 29% of eyes achieved IOP ≤ 12 mmHg, versus 7% preoperatively.Fig. 1Change in average intraocular pressure (*n* = 118). Following cataract surgery combined with implantation of iStent Inject, mean intraocular pressure significantly decreased and was maintained throughout follow-up (*p* \< 0.001).*Asterisk*signifies statistical differences at *p* \< 0.05;*bars* demonstrate standard error of the mean; *IOP* intraocular pressureTable 2Twelve-month outcomes in efficacy and safety measures (*N* = 118 eyes of 71 subjects)VariableBaseline12-Month follow-up*η*^2^*p* valueIntraocular pressure (mmHg)17.00 ± 3.8213.97 ± 2.650.411**\<** 0.001\*Glaucoma medications2.31 ± 1.331.03 ± 1.100.680**\<** 0.001\*Corrected distance visual acuity (LogMAR)0.17 ± 0.220.10 ± 0.170.163**\<** 0.001\*Cup to disc ratio0.70 ± 0.120.69 ± 0.130.0230.113Visual field---mean deviation (dB)− 6.57 ± 6.09− 6.49 ± 6.040.0010.729Visual field---pattern standard deviation (dB)4.59 ± 2.784.67 ± 2.840.0030.567Retinal nerve fiber layer thickness (μm)71.10 ± 12.6271.61 ± 12.940.0160.184Ganglion cell inner plexiform layer thickness (μm)67.72 ± 9.1267.79 ± 9.880.0000.906Mean ± standard deviations are presented and statistically compared\*Denotes statistical significanceFig. 2Percentages of eyes with IOP ≤ 18, ≤ 15, and ≤ 12 mmHg (*n* = 118) preoperatively and at 1-year follow-up.*Solid bars* and*diagonally hashed bars* represent preoperative and 1-year follow-up data, respectively. *IOP* intraocular pressure

Mean medication burden decreased by 56% to 1.03 ± 1.10 medications from the preoperative mean of 2.31 ± 1.33 (*p* \< 0.001, *η*^2^ = 0.680, 95% CI − 1.45 to − 1.13) (Fig. [3](#Fig3){ref-type="fig"}, Table [2](#Tab2){ref-type="table"}). All 118 eyes either maintained or decreased their topical medication burden compared to their preoperative usage, with ≥ 1 medication eliminated from the original regimen for 83% of the eyes and ≥ 2 medications eliminated for 36% of the eyes (Fig. [4](#Fig4){ref-type="fig"}). At 12 months postoperatively, 47% of the eyes were medication-free compared to 4% preoperatively, and only 40% of the eyes were on ≥ 2 medications, as opposed to 67% preoperatively.Fig. 3Change in mean number of glaucoma medications (*n* = 118). Following cataract surgery combined with implantation of iStent Inject, the mean number of medications significantly decreased, and this was maintained throughout follow-up (*p* \< 0.001).*Asterisk*signifies statistical differences at *p* \< 0.05;*bars*demonstrate standard error of the meanFig. 4Proportions of the eyes with reductions of ≥ 0, ≥ 1, or ≥ 2 medication(s) at t 12 months.*Solid bars* represent the 1-year follow-up data. *Med* medication

A linear regression model was created to identify predictors of postoperative IOP improvement (Table [3](#Tab3){ref-type="table"}). The model showed that greater baseline preoperative IOP (*β* = − 0.772, *p* \< 0.001) and thinner corneas (*β* = 0.148, *p* = 0.042) were associated with a larger postoperative IOP reduction. A second model was created to identify predictors of postoperative medication reduction (*R*^2^ = 0.361, adjusted *R*^2^ = 0.376, *p* \< 0.001), which showed that a higher number of glaucoma medications at baseline was associated with a greater reduction in medication burden postoperatively (*β* = − 0.629, *p* \< 0.001). Differences in age, sex, type, and severity of glaucoma and in prior history of glaucoma surgery did not account for the amount of IOP or medication reduction in either model.Table 3Linear regression models for baseline predictors of improvements in IOP and medication burden at 1 year postoperatively (*N* = 118 eyes of 71 subjects)Independent variable*Bβt* value*p* value95% CIIntraocular pressure (*R*^2^ = 0.591, adjusted *R*^2^ = 0.557, *p* \< 0.001) Age (years)− 0.004− 0.011− 0.1430.887− 0.0670.058 Sex0.1300.0180.2580.797− 0.8661.125 Glaucoma subtype0.1120.0370.5380.592− 0.3010.525 Previous glaucoma intervention− 0.139− 0.019− 0.2630.793− 1.1880.910 Central corneal thickness (µm)0.0140.1482.0630.042\*0.0010.027 Baseline intraocular pressure (mmHg)− 0.737− 0.772− 11.459\< 0.001\*− 0.864− 0.609 Baseline medication burden0.2000.0731.0150.313− 0.1910.591 Visual field---mean deviation (dB)0.0300.0520.7290.468− 0.0520.112Medication burden (*R*^2^ = 0.361, adjusted *R*^2^ = 0.376, *p* \< 0.001) Age (years)− 0.004− 0.038− 0.4000.690− 0.0230.015 Sex0.1090.0620.7130.477− 0.1940.412 Glaucoma subtype0.0550.0750.8710.386− 0.0710.181 Previous glaucoma intervention0.1140.0640.7080.481− 0.2060.433 Central corneal thickness (µm)0.000− 0.010− 0.1110.912− 0.0040.004 Baseline intraocular pressure (mmHg)0.0280.1231.4550.149− 0.0100.067 Baseline medication burden− 0.419− 0.629− 6.988\< 0.001\*− 0.539− 0.300 Visual field---mean deviation (dB)0.000− 0.001− 0.0060.995− 0.0250.025*B* regression coefficient, *β* standardized coefficient beta, *CI* confidence interval\*Denotes statistical significance

As iStent is indicated for POAG with mild to moderate severity, we performed a subgroup analysis for eyes that met that criterion. Fifty-three eyes with an average age of 70.26 ± 8.74 years and a mean baseline IOP of 17.28 ± 3.55 mmHg on an average of 2.09 ± 1.15 antiglaucoma medications were included. The subgroup outcomes were similar to those of the overall cohort: IOP decreased by 19.0% to 14.00 ± 2.47 mmHg (*p* \< 0.001, *η*^2^ = 0.482, 95% CI − 4.23 to − 2.34) and medication burden decreased by 62.2% to 0.79 ± 0.93 (*p* \< 0.001, *η*^2^ = 0.730, 95% CI − 1.52 to − 1.08).

Safety Measurements {#Sec9}
-------------------

All eyes were successfully implanted with two iStent Inject stents with no intraoperative complications. Postoperatively, CDVA improved significantly, consistent with the expectations for cataract surgery (*p* \< 0.001, *η*^2^ = 0.163, 95% CI  0.045--0.110). Additionally, stability was maintained for 12 months in patients' CDR (*p* = 0.113), VF MD (*p* = 0.729), and thicknesses of the retinal nerve fiber layer (*p* = 0.184) and ganglion cell inner plexiform layer (*p* = 0.906).

Relatively few adverse events occurred and all were transient, had no sight-threatening sequelae, and were managed conservatively. Adverse events included IOP spike (defined as IOP greater than 50% above baseline \[[@CR31]\]) in 11% of the eyes within the first two postoperative weeks, which can be attributed to the postoperative steroid regimen, and microhyphema in 5% of the eyes within the first 24 h after surgery, which can be expected with ocular surgery. Other events that are common after cataract surgery (and are unrelated to stents) included transient corneal edema 24 h after surgery in 10% of the eyes, posterior capsular opacification within the first six postoperative months in 8% of the eyes, and rebound iritis in 6% of the eyes within the first postoperative month. Notably, there were no reports of hypotony, choroidal detachment, stent obstruction, stent extrusion, peripheral anterior synechiae (PAS), myopic shift, or endophthalmitis. During follow-up, only three eyes underwent selective laser trabeculoplasty: one for persistent elevated IOP and two for intolerance to antiglaucoma drops and the need for IOP reduction without pharmacotherapy. Importantly, no increase in the number of antiglaucoma medications was documented postoperatively, and no eye needed incisional secondary glaucoma surgeries during follow-up.

Discussion {#Sec10}
==========

A surgical device to treat glaucoma---especially a device with favorable safety and durable effectiveness---has many advantages over medication therapy. Suboptimal medication adherence can be a significant obstacle to achieving disease control, and poor adherence has been shown to promote disease progression \[[@CR32]--[@CR35]\]. Additionally, even in the setting of perfect adherence, normal diurnal variations in intraocular drug activity may permit IOP fluctuations that increase the risk of optic nerve damage \[[@CR36], [@CR37]\]. Comparatively, surgical treatments have been proven to have less IOP variability than medications \[[@CR38], [@CR39]\]. Thus, an implanted device that delivers a consistent IOP reduction independently of external factors avoids both the adherence issues and IOP fluctuations inherent in medication usage. The safe and sustained IOP- and medication-reducing outcomes of the present study indicate that the iStent Inject trabecular micro-bypass stent is a favorable option, with cataract surgery offering an opportune moment for their implantation. Furthermore, this micro-invasive, ab interno implantation procedure preserves conjunctival tissue in case future surgery is needed.

The IOP and medication reductions of the present study are consistent with prior evaluations of second-generation iStent Inject trabecular bypass stents combined with cataract surgery for open-angle glaucoma \[[@CR27], [@CR40]--[@CR42]\]. Mean IOP was reduced by 2.75 mmHg (16.2%), a modest IOP reduction that should be considered in the context of the cohort's low mean preoperative IOP of 17.00 mmHg. Since it is lower than in most existing studies of trabecular bypass stents, the cohort's low mean preoperative IOP makes it more difficult to achieve large postoperative IOP reductions. Given that glaucoma may continue to progress in many patients despite them having an IOP in the normal range \[[@CR43]\], and the fact that each 1 mmHg reduction in IOP leads to a 10% reduction in the risk of glaucoma progression \[[@CR44]\], the goal for surgery in these patients was to achieve an even lower IOP while also reducing the medication burden.

Most of the evidence in the literature on iStent Inject revolves around the outcomes related to POAG patients with mild to moderate severity---the population for whom this device is approved. We performed a subgroup analysis for eyes that met these criteria, but we also report outcomes of the overall dataset, including off-label use in PACG and severe glaucoma cases. The performance of the device for these indications has not been formally established in prospective randomized controlled trials, and thus additional caution was taken before undertaking device implantation in these patients. In PACG cases specifically, all eyes had a previous LPI, and adequate visualization of the nasal angle structures was ensured prior to implantation of the stent. Interestingly, the regression analyses did not show any impact of glaucoma subtype or severity on the degree of IOP and medication reduction. This lack of association suggests that iStent Inject may be effective in a wide range of glaucoma subtypes and severities, including in non-POAG cases and severe glaucoma cases. In line with our findings, other recent studies have also shown significant IOP and medication reductions in patients with narrow-angle glaucoma, PXFG, and severe glaucoma following combined iStent Inject implantation and cataract surgery \[[@CR45], [@CR46]\].

With regard to medications, the cohort exhibited a notable 67% decrease in mean number of medications---a number which is further supported by the literature, with previous studies reporting 1-year medication reductions ranging from 56 to 77% \[[@CR20], [@CR21], [@CR40], [@CR42]\]. As evidenced by our regression model, those with higher preoperative medication burdens experienced larger medication reductions postoperatively. At the level of individual patients, medications were maintained or decreased for all eyes versus their preoperative state; one medication was eliminated for 83% of the eyes, two were eliminated for 43% of the eyes, and medications were eliminated entirely for close to half of the eyes (46%). Since medication burden is known to impact patient compliance and quality of life \[[@CR47]--[@CR49]\], this combined surgery may produce benefits beyond simply gaining better IOP control with fewer drops.

Importantly, the IOP- and medication-reducing performance was sustained for 12 months within our heterogeneous glaucoma population, which consisted of different glaucoma subtypes and severities. As such, we believe that our findings are pertinent to practicing ophthalmologists evaluating treatment options for glaucoma patients in real-world clinical settings. Finally, another unique aspect of this study is that the surgical technique included the identification of collector channels with the goal of facilitating stent placement adjacent to the episcleral vessels and optimizing outflow. This strategy is based upon prior work showing a correlation between greater episcleral venous outflow and better IOP outcomes \[[@CR50]\]. The findings of our study are similar to those of multiple other studies in which collector channels were not specifically identified prior to stent placement \[[@CR27], [@CR40]--[@CR42]\]. This can be interpreted in light of a variety of explanations. Our ability to assess the integrity and function of the collector channel preoperatively is limited, and it is possible that the collector channels identified were subject to distal atrophy \[[@CR51]\]. Additionally, despite our effort to precisely identify the collector channels, we cannot rule out accuracy errors. Alternatively, considering our findings, it can be argued that iStent Inject has a beneficial impact independently of collector channel identification.

The safety profile of the iStent Inject device was highly favorable, with no intraoperative complications, relatively minimal and mild postoperative adverse events, and thus no significant sequelae. Visual acuity improved significantly, consistent with expectations for cataract surgery, and indicating that stent implantation has no untoward effects on the visual benefits of cataract surgery. Safety outcomes also showed that CDR, VF MD, and RNFL and GCIPL thicknesses remained stable postoperatively for 12 months. Given the established association between elevated IOP and thinning of the RNFL and GCIPL \[[@CR3]\], the IOP-lowering effect of the iStent Inject may conceivably reduce the risk of neuronal loss. Furthermore, patients did not exhibit the side effects or adherence issues of topical medication \[[@CR4]--[@CR6]\], did not show the waning IOP- and medication-reducing effectiveness of laser trabeculoplasty \[[@CR7]\], and did not demonstrate the safety risks seen with filtering surgery \[[@CR8]--[@CR10]\]. There were no reports of complications seen with traditional filtering surgeries or some other MIGS modalities, such as PAS, hypotony, choroidal detachment, stent obstruction, stent extrusion, stent--endothelial contact, or endophthalmitis \[[@CR8]--[@CR10], [@CR52], [@CR53]\]. While longer-term data are needed to confirm stability over time, these initial safety outcomes are reassuring.

This study has some limitations. The lack of a control arm limits our findings to the efficacy of the combined procedure as opposed to the efficacy of iStent Inject as a standalone procedure. To address this limitation, we focused our discussion and interpretation around comparing the results to evidence previously reported for combined procedures. Additionally, our study was limited to only one surgeon and clinical site. Although this factor limits the sample size, it favors the results by limiting bias due to intersurgeon differences in examination and surgical techniques. Consistent with most real-world clinical reports, patients did not complete a preoperative medication washout, as this is not indicated or appropriate in routine clinical practice. Outcomes included 12 months of follow-up, so future research could be done over longer periods of data collection, as well as with patients from multiple sites and/or with larger sample sizes. Future research could also include separate studies of individual glaucoma subtypes or analyses with greater numbers of participants to allow for different stratified analyses.

Conclusion {#Sec11}
==========

The present study provides clinically relevant, real-world data on the utility of second-generation iStent Inject trabecular bypass stents with cataract surgery in a heterogeneous, robustly sized patient population. The surgery led to meaningful patient-level reductions in medication burden as well as significantly lower IOP. IOP and medication reductions were sustained postoperatively for 12 months, conjunctival tissue was not disturbed, and safety was favorable. These findings, which were observed within a heterogeneous glaucoma population and thus are generalizable to many practicing ophthalmologists, suggest that iStent Inject trabecular micro-bypass implantation with phacoemulsification is a safe, consistently efficacious, tissue-preserving glaucoma treatment option for patients with cataract and various types of mild to severe glaucoma.
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